LQD® Spray is, as the name suggests, a spray-on primary dressing that is indicated for the external, local treatment of chronic wounds (such as leg ulcers and diabetic foot ulcers) ,acute wounds and epidermal and superficial partial-thickness burns.


LQD SparyLQD® Spray has a number of benefits that make it stand out as an innovative product for use in wound management.

First is ease of application. Several clinicians have evaluated the product in various clinical settings from leg ulcer and diabetic foot ulcer clinics to mental health trusts and secure units. All have found the ease of use to be a huge benefit.  It can be used easily and safely by all healthcare professionals delivering care, and can also be easily applied by patients themselves where appropriate.
After cleansing the wound, LQD Spray is simply sprayed onto the wound bed, where within 2 minutes, it dries to form a chitosan-containing dressing that conforms perfectly to the wound bed. LQD Spray is a primary dressing so there is no need to cover, although an appropriate secondary dressing can be applied if it is considered clinically necessary.

The dressing is removed either as part of standard wound cleaning or during the process of natural skin renewal.

The unique application of LQD Spray and the fact that the dressing contours to the wound bed makes it ideal to apply to those anatomical positions that are difficult to dress using traditional wound dressings. LQD Spray has also been found to be of benefit for wound management in patient groups where dressing removal and tampering can be a challenge, such as patients with wounds and severe mental illness or those who self-harm. 

“The ‘idea’ of LQD Spray was very appealing for my line of work especially selfharm wounds.  LQD Spray performed just as I had hoped and I would like to add it to my ‘toolkit’ following further evaluations. LQD Spray is cost effective and is perfectly suited to my field of work due to the risk of wound infection and the ingestion of dressings, and will be also useful in promoting self-care. ‘
Adele Linthwaite, Tissue Viability Lead & Continence Advisor, Birmingham and Solihull Mental Health NHS Foundation Trust

The active ingredient; Chitosan FH02

The main component of LQD Spray is Chitosan-FH02. Chitosan is derived from a naturally occurring biopolymer, Chitin, during a process that involves deacetylation. This gives the chitosan Biopolymer the positive charge that is proven to give it its antimicrobial properties and ability to positively influence wounds at every stage (Dai et al, 2011). The Chitosan in LQD Spray is modified to become the innovative Chitosan FH02 which has a higher positive charge and the highest degree of de-acetylation of any Chitosan product. This makes it more potent in terms of its mode of action, and results in beneficial wound healing outcomes.
Mode of action
Studies have reported that Chitosan can positively influence the speed of healing and there is good evidence to suggest it has a role to play in each stage of the wound healing process (Dai et al, 2011).
Studies have shown that Chitosan is a natural haemostat, with the ability to bind with red blood cells causing rapid blood clotting (Kozen et al, 2008).  (Foda et al, 2007; Lee et al, 2009).

Chitosan also stimulates the immune response by encouraging the migration of essential leukocytes and macrophages to the wound site (Lee et al, 2009). 
Chitosan is also able to modulate the function of inflammatory cells within the wound and therefore promote granulation tissue formation (Ueno et al, 2001). Chitosan has been shown to enhance the functions of inflammatory cells, such as polymorphonuclear leukocytes (PMN) macrophages and fibroblasts (Ueno et al, 2001).
Chitosan has been shown to assist in the granulation and epithelializing stages of wound healing by stabilising fibroblasts and promoting keratinocyte proliferation.

Furthermore, Chitosan also assists in the laying down of collagen, helps with wound tensile strength and also influences scarring through interaction with TGFb. It influences the behaviour of growth factors to stimulate healing.

Antimicrobial action
Chitosan is a natural anti-microbial which can be effective in preventing and treating infections. The positive charged Chitosan molecule interacts with the negative charge on the cell wall of the bacteria, disrupting the cell wall structure and causing the contents of the bacteria to leak out (Rabea et al, 2003).

Finally, Chitosan is nontoxic, biocompatible and is biodegradable (Dai et al, 2011). Chitosan FH02 is also ultra-pure as it is derived for medicinal use and is not exposed to any contaminants during processing.


In a UK case series of 60 patients from 10 care settings, involving several chronic wound types (venous leg ulcers, n=35; diabetic foot ulcers,  n=9; pressure ulcer / moisture lesions, n=9; wounds in patients with mental health comorbidities, n =9) healing was achieved within 12 weeks in 49/60 (82%) of cases. This was despite the wound not healing normally using other treatments in accordance with best practice for wound type before LQD Spray was applied. In wounds that did not heal, reduction in size was seen in most cases (Hampton, 2018; Sharp et al, 2018).

Positive patient feedback resulting from wound progression following prolonged periods of chronicity was also received, with a decrease in pain often reported.
‘Having used the LQD spray in a number of patients with diabetic foot ulceration (DFU) we found it improved outcomes, especially where the wound had all other standards of care in place, such as off-loading and control of ischaemia. We have used LQD Spray with a range of DFUs and even in patients who we did not manage to heal we often visually observed an improvement in the wound bed, in particular reduction in size.’

Andrew Sharpe BSc (Hons) MSC HCPC MCHS Advanced Podiatrist & Team Leader
West Lancashire Community Care  
‘The use of LQD Spray promoted epithelialisation and granulation in both venous leg ulcers and diabetic foot ulcers, despite some of the patients having complex co-morbidities that had resulted in making wounds difficult to heal. In these patients, LQD Spray stimulated and accelerated healing in wounds that had previously not healed despite best practice wound management. In other patients, wound size was greatly reduced, and the wound placed on a healing trajectory.

The use of LQD Spray greatly benefitted the patients treated. The burden of living with a chronic wound should not be under-estimated, and the patients were delighted to finally have their wounds healed; they had been present for months in some cases.’ ​

Joy Tickle, Tissue Viability Specialist Shropshire Community NHS Trust


LQD Spray is supplied in a 12ml bottle at a cost of £45.00 and each spray delivers 0.1ml, meaning each bottle contains 120 sprays. This works out at £0.37p per spray. During the clinical evaluations collated to date in the UK, we have shown that in many cases only two sprays were needed to achieve an effective dressing (i.e. an effective dressing cost of £0.75); and that based on 120 actuations per 12ml bottle (12 weeks’ treatment), product wastage is not an issue. 

Over a 12-week period, LQD costs £3.75 per week which is lower than many wound dressings on the market.  

In 67% (40/60) of the patients involved in the UK evaluations, LQD Spray was used to replace one or more dressing products with an average cost saving of £4.16 per patient per week.  

For more information on LQD Spray, please visit https://www.lqdspray.com


Dai T, Tanaka M Huang YY and Hamblin MR (2011) Chitosan preparations for wounds and burns: antimicrobial and wound- healing effects Expert Rev Anti Infect Ther 9(7): 857–79. doi: 10.1586/eri.11.59

Foda NH, El-laithy HM, Tadros MI (2007) Implantable biodegradable sponges: effect of interpolymer complex formation of chitosan with gelatin on the release behavior of tramadol hydrochloride. Drug Dev Ind Pharm 33(1): 7–17

Hampton S (2018) A new spray-on chitosan FH02 dressing for venous leg ulcers: an evaluation. JCN 32(3): 1–4

Kozen BG, Kircher SJ, Henao J, et al (2008) An alternative hemostatic dressing: comparison of CELOX, HemCon, and QuikClot. Acad Emerg Med 15(1): 74–81

Lee DW, Lim H, Chong HN, Shim WS (2009) Advances in chitosan material and its hybrid derivatives: a review. The Open Biomaterials Journal 1: 10–20

Sharp A, Tickle J, Hampton S, Gray D (2018) A multicentre evaluation of a new chitosan FH02 spray-on dressing in patients with chronic wounds in the UK. JCN 32(2): 1–7

Ueno H, Mori T, Fujinaga T ( 2001) Topical formulations and wound healing applications of chitosan. Adv Drug Deliv Rev 52(2): 105–15